Oxaydo Patent Expiration

Oxaydo is a drug owned by Zyla Life Sciences Us Inc. It is protected by 6 US drug patents filed from 2013 to 2016 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 16, 2025. Details of Oxaydo's patents and their expiration are given in the table below.

Patent strength
1
/ 10

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7201920 Methods and compositions for deterring abuse of opioid containing dosage forms
Mar, 2025

(11 months ago)

Expired
US9492443 Abuse deterrent compositions and methods of making same
May, 2024

(1 year, 9 months ago)

Expired
US8409616 Extended release opioid abuse deterrent compositions and methods of making same
Nov, 2023

(2 years ago)

Expired
US8637540 Compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(2 years ago)

Expired
US7510726 Methods and compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(2 years ago)

Expired
US7981439 Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
Nov, 2023

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxaydo's patents.

Given below is the list of recent legal activities going on the following patents of Oxaydo.

Activity Date Patent Number
Patent litigations
Expire Patent 05 May, 2025 US8409616
Change in Power of Attorney (May Include Associate POA) 25 Feb, 2025 US7201920 (Litigated)
Email Notification 25 Feb, 2025 US7201920 (Litigated)
Expire Patent 23 Dec, 2024 US9492443
Maintenance Fee Reminder Mailed 18 Nov, 2024 US8409616
Maintenance Fee Reminder Mailed 08 Jul, 2024 US9492443
Expire Patent 21 Aug, 2023 US7981439
Maintenance Fee Reminder Mailed 06 Mar, 2023 US7981439
Email Notification 15 Mar, 2022 US8637540
Change in Power of Attorney (May Include Associate POA) 15 Mar, 2022 US9492443

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Oxaydo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxaydo's family patents as well as insights into ongoing legal events on those patents.

Oxaydo's Family Patents

Oxaydo has patent protection in a total of 6 countries. It has a significant patent presence in the US with 52.0% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Oxaydo.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Oxaydo's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 16, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Oxaydo Generic API suppliers:

Oxycodone Hydrochloride is the generic name for the brand Oxaydo. 26 different companies have already filed for the generic of Oxaydo, with Epic Pharma Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Oxaydo's generic

How can I launch a generic of Oxaydo before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Oxaydo's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Oxaydo's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Oxaydo -

Strength Submission Date Expiration Date of Last Qualifying Patent 180-Day Status First Applicant Approval Generic Competition Status
25 mg / 5 mL
🔒 Unlock
07 Feb, 2012 16 Mar, 2025 Extinguished Less


Alternative Brands for Oxaydo

There are several other brand drugs using the same active ingredient (Oxycodone Hydrochloride) as Oxaydo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Mallinckrodt Inc
Xartemis Xr
Pfizer
Troxyca Er
Protega Pharms
Roxybond
Purdue Pharma Lp
Oxycontin
Targiniq


Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxycodone Hydrochloride, Oxaydo's active ingredient. Check the complete list of approved generic manufacturers for Oxaydo





About Oxaydo

Oxaydo is a drug owned by Zyla Life Sciences Us Inc. Oxaydo uses Oxycodone Hydrochloride as an active ingredient. Oxaydo was launched by Zyla in 2011.

Approval Date:

Oxaydo was approved by FDA for market use on 17 June, 2011.

Active Ingredient:

Oxaydo uses Oxycodone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Oxycodone Hydrochloride ingredient

Dosage:

Oxaydo is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
7.5MG TABLET Discontinued ORAL
5MG TABLET Discontinued ORAL